Repligen completes acquisition of BioLife Solutions
Repligen Corporation has closed its previously announced acquisition of Nasdaq-listed BioLife Solutions, a developer of cell processing tools and biopreservation media for the cell and gene therapy market. BioLife's CryoStor-led portfolio supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based trials, adding what Repligen calls a high-margin consumables business with recurring revenue to its bioprocessing lineup.
Why it matters: The deal pushes Repligen deeper into cell and gene therapy workflows, a growth pocket of life sciences tools where embedded consumables command durable revenue.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.
See what you get →